Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OBIO Stock Forecast 2026-2027
$3.82
Current Price
$228.74M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to OBIO Price Targets
+423.6%
To High Target of $20.00
+161.8%
To Median Target of $10.00
+135.6%
To Low Target of $9.00
OBIO Price Momentum
-3.5%
1 Week Change
-6.8%
1 Month Change
+26.1%
1 Year Change
-8.0%
Year-to-Date Change
-29.6%
From 52W High of $5.42
+73.6%
From 52W Low of $2.20
📊 TOP ANALYST CALLS
Did OBIO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Health Sciences Acquisitions 2 is one of their latest high-conviction picks.
Latest OBIO Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, OBIO has a bullish consensus with a median price target of $10.00 (ranging from $9.00 to $20.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $3.82, the median forecast implies a 161.8% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OBIO Analyst Ratings
6
Buy
1
Hold
0
Sell
OBIO Price Target Range
Low
$9.00
Average
$10.00
High
$20.00
Current: $3.82
Latest OBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OBIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 19, 2026 | B. Riley Securities | Kyle Bauser | Buy | Maintains | $10.00 |
| May 14, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $10.00 |
| May 13, 2026 | Barclays | Matt Miksic | Overweight | Maintains | $13.00 |
| Mar 12, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Jan 9, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Dec 10, 2025 | TD Cowen | Buy | Initiates | $N/A | |
| Nov 13, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 12, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Sep 4, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 20, 2025 | BTIG | Neutral | Downgrade | $N/A | |
| Aug 13, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Aug 7, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| May 13, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| May 5, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Apr 22, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Apr 4, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 1, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 20, 2025 | BTIG | Buy | Initiates | $N/A | |
| Mar 10, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 2, 2025 | Barclays | Overweight | Initiates | $N/A |
Orchestra BioMed Holdings, Inc. (OBIO) Competitors
The following stocks are similar to Health Sciences Acquisitions 2 based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
OBIO
Health Sciences Acquisitions Corp 2
mkt cap
238.92M
Orchestra BioMed Holdings, Inc. (OBIO) Financial Data
Orchestra BioMed Holdings, Inc. has a market capitalization of $228.74M with a P/E ratio of -3.4x. The company generates $32.72M in trailing twelve-month revenue with a -167.0% profit margin.
Revenue growth is -87.3% quarter-over-quarter, while maintaining an operating margin of -20,069.1% and return on equity of -161.1%.
Valuation Metrics
Market Cap
$228.74M
Enterprise Value
$170.15M
P/E Ratio
-3.4x
PEG Ratio
0.1x
Price/Sales
7.3x
Growth & Margins
Revenue Growth (YoY)
-87.3%
Gross Margin
+70.9%
Operating Margin
-20,069.1%
Net Margin
-167.0%
EPS Growth
-87.3%
Financial Health
Cash/Price Ratio
+41.3%
Current Ratio
7.0x
Debt/Equity
31.1x
ROE
-161.1%
ROA
-43.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Orchestra BioMed Holdings, Inc. (OBIO) Business Model
About Orchestra BioMed Holdings, Inc.
What They Do
Develops innovative biomedical therapies for healthcare.
Business Model
The company focuses on developing and commercializing advanced medical therapies, particularly in the cardiovascular space, through its bioelectronics and delivery platform. It generates revenue by partnering with major healthcare organizations to expedite the development of its solutions, thereby addressing unmet medical needs and improving patient outcomes.
Additional Information
Orchestra BioMed is committed to transforming patient care and has a strong presence in the healthcare sector, positioning itself as a key player in the integration of technology and clinical applications.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
86
CEO
Mr. David P. Hochman
Country
United States
IPO Year
2020
Website
www.orchestrabiomed.comOrchestra BioMed Holdings, Inc. (OBIO) Latest News & Analysis
Latest News
Quick Summary
Orchestra BioMed Holdings, Inc. has been added to the Russell 3000® and Russell 2000® Indexes following the 2026 reconstitution, effective June 26, 2026.
Why It Matters
Orchestra BioMed's inclusion in the Russell 3000 and Russell 2000 indexes enhances visibility and liquidity, potentially attracting more institutional investors and driving stock demand.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Orchestra BioMed granted stock options for 85,500 shares to five new employees as part of its 2025 New Hire Inducement Plan. The options will vest over four years.
Why It Matters
The granting of stock options to new employees signals confidence in future growth and aligns employee interests with shareholder value, potentially enhancing company performance and stock price.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) will participate in the Jefferies Global Healthcare Conference, as announced on May 19, 2026.
Why It Matters
Orchestra BioMed's participation in a major healthcare conference signals potential investor interest, visibility, and opportunities for partnerships that could enhance its market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
2 months ago
Quick Summary
Orchestra BioMed plans to complete enrollment for the BACKBEAT Trial by Q3 2026, with primary endpoint data presentation set for Q2 2027. Medtronic aims for FDA marketing application post-trial results.
Why It Matters
Orchestra BioMed's update on the BACKBEAT Trial and collaboration with Medtronic could lead to significant advancements in treatment for hypertension, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
2 months ago
Quick Summary
Orchestra BioMed Holdings reported Q1 2026 financial results, highlighting progress in Atrioventricular Interval Modulation Therapy and Virtue Sirolimus AngioInfusion Balloon, backed by a strong balance sheet.
Why It Matters
Orchestra BioMed's strong Q1 results and progress in pivotal-stage programs indicate potential growth and value, which can attract investors seeking opportunities in innovative biomedical technologies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Orchestra BioMed reported a quarterly loss of $0.33 per share, better than the expected loss of $0.40 and improved from a loss of $0.49 per share a year earlier.
Why It Matters
Orchestra BioMed's smaller-than-expected quarterly loss indicates improving financial health, potentially boosting investor confidence and affecting stock performance positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About OBIO Stock
What is Orchestra BioMed Holdings, Inc.'s (OBIO) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Orchestra BioMed Holdings, Inc. (OBIO) has a median price target of $10.00. The highest price target is $20.00 and the lowest is $9.00.
Is OBIO stock a good investment in 2027?
According to current analyst ratings, OBIO has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.82. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OBIO stock?
Wall Street analysts predict OBIO stock could reach $10.00 in the next 12 months. This represents a 161.8% increase from the current price of $3.82. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Orchestra BioMed Holdings, Inc.'s business model?
The company focuses on developing and commercializing advanced medical therapies, particularly in the cardiovascular space, through its bioelectronics and delivery platform. It generates revenue by partnering with major healthcare organizations to expedite the development of its solutions, thereby addressing unmet medical needs and improving patient outcomes.
What is the highest forecasted price for OBIO Orchestra BioMed Holdings, Inc.?
The highest price target for OBIO is $20.00 from at , which represents a 423.6% increase from the current price of $3.82.
What is the lowest forecasted price for OBIO Orchestra BioMed Holdings, Inc.?
The lowest price target for OBIO is $9.00 from at , which represents a 135.6% increase from the current price of $3.82.
What is the overall OBIO consensus from analysts for Orchestra BioMed Holdings, Inc.?
The overall analyst consensus for OBIO is bullish. Out of 4 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are OBIO stock price projections?
Stock price projections, including those for Orchestra BioMed Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 1:26 PM UTC